Hologic (NASDAQ:HOLX) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Hologic (NASDAQ:HOLX) in a research report released on Wednesday, AnalystRatings.com reports. They currently have a $52.00 target price on the medical equipment provider’s stock.
“FDA’s latest monthly Act (MQSA) statistics were published on 7/1/19. The number of digital breast tomosynthesis (DBT) units increased by 92 during June which represents a 30.8% Y/Y decrease. DBT unit penetration increased to 37.3% from 37.0% last month and facility penetration increased to 62.1% from 61.4% last month. More importantly, DBT units placements were up 2.7% quarter-to-date (QTD) in 2Q19 vs. 2Q18. We note that HOLX’s 3D mammography sales are less than 13% of its total sales. Please contact your Needham salesperson for a copy of our MQSA spreadsheet.”,” the firm’s analyst wrote.
Other equities analysts also recently issued reports about the stock. BTIG Research boosted their target price on shares of Yum! Brands to $114.00 and gave the stock a buy rating in a report on Thursday, May 2nd. TheStreet downgraded shares of ZTO Express (Cayman) from a b+ rating to a c rating in a report on Wednesday, May 1st. ValuEngine upgraded shares of China Southern Airlines from a sell rating to a hold rating in a report on Tuesday, June 11th. Zacks Investment Research upgraded shares of Hudson Technologies from a sell rating to a hold rating in a report on Wednesday, May 29th. Finally, BidaskClub downgraded shares of ZIX from a strong-buy rating to a buy rating in a report on Friday, June 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $45.02.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, May 1st. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.01. The firm had revenue of $818.40 million during the quarter, compared to the consensus estimate of $806.99 million. Hologic had a positive return on equity of 26.73% and a negative net margin of 0.32%. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. On average, research analysts predict that Hologic will post 2.42 earnings per share for the current fiscal year.
In other news, insider Peter J. Valenti III sold 4,545 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $44.07, for a total transaction of $200,298.15. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.90% of the stock is currently owned by insiders.
Several hedge funds have recently modified their holdings of the company. Mason Street Advisors LLC grew its stake in shares of Hologic by 0.6% during the first quarter. Mason Street Advisors LLC now owns 38,204 shares of the medical equipment provider’s stock worth $1,849,000 after acquiring an additional 222 shares during the last quarter. Moody National Bank Trust Division boosted its position in Hologic by 1.1% in the first quarter. Moody National Bank Trust Division now owns 28,269 shares of the medical equipment provider’s stock valued at $1,368,000 after buying an additional 294 shares during the last quarter. First Hawaiian Bank boosted its position in Hologic by 3.2% in the first quarter. First Hawaiian Bank now owns 10,278 shares of the medical equipment provider’s stock valued at $497,000 after buying an additional 320 shares during the last quarter. Ledyard National Bank boosted its position in Hologic by 4.2% in the first quarter. Ledyard National Bank now owns 9,820 shares of the medical equipment provider’s stock valued at $475,000 after buying an additional 400 shares during the last quarter. Finally, MML Investors Services LLC boosted its position in Hologic by 6.8% in the fourth quarter. MML Investors Services LLC now owns 6,441 shares of the medical equipment provider’s stock valued at $265,000 after buying an additional 412 shares during the last quarter. Institutional investors and hedge funds own 96.38% of the company’s stock.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
See Also: Market Perform
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.